An Open-label Phase 1/2a Study of BAL101553 Administered as Intravenous 48-hour Infusions in Adult Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 10 Aug 2017
At a glance
- Drugs BAL 101553 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Basilea Pharmaceutica
- 10 Aug 2017 Completion of patient recruitment into this trial is expected in the first half of 2018 according to a Basilea Pharmaceutica media release.
- 06 Jun 2017 According to a Basilea Pharmaceuticals media release, the company expected completion of dose-escalation towards the end of 2017.
- 06 Jun 2017 According to a Basilea Pharmaceuticals media release, interim data was presented at the the American Society of Clinical Oncology (ASCO) annual meeting 2017.